Neogenomics Inc is primarily active in the healthcare and diagnostic laboratory services industries.

The main competitors of Neogenomics Inc in the market are Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, and NeoGenomics Laboratories.

Neogenomics Inc is a leading provider of cancer-focused genetic testing services. Founded in 2001, the company is headquartered in Fort Myers, Florida. With an extensive network of laboratories across the United States, Neogenomics offers cutting-edge diagnostic and pharmaceutical services to aid in the personalized treatment and monitoring of various types of cancers. Over the years, Neogenomics has grown its portfolio of tests and services, catering to the evolving needs of healthcare professionals and patients. Their dedication to innovation and quality has positioned them as a trusted partner in the fight against cancer.

Some significant milestones achieved by Neogenomics Inc include its acquisition of Clarient Inc in 2015, which expanded its personalized medicine capabilities. The company also received full approval from the New York State Department of Health in 2017, allowing it to offer its services in all 50 states. Neogenomics Inc has strengthened its position in the molecular testing market through strategic collaborations with pharmaceutical companies. Furthermore, in 2019, the company completed its acquisition of Genoptix, enhancing its oncology diagnostics capabilities. These milestones demonstrate Neogenomics Inc's commitment to growth and innovation in the field of cancer diagnostics and personalized medicine.

Neogenomics Inc is primarily present in the United States.

Neogenomics Inc prides itself on its commitment to excellence and innovation in the field of precision medicine. With a strong corporate philosophy centered around patient care and advancing the fight against cancer, Neogenomics Inc places great importance on ethical practices and providing accurate diagnostic solutions. The company believes in fostering a collaborative environment to bring cutting-edge technologies and personalized medicine to patients globally. By constantly pushing boundaries and embracing transformative ideas, Neogenomics Inc aims to revolutionize how cancer is detected and treated. Through its dedication to quality, integrity, and patient-centric values, the company sets itself apart as a leader in the field.

Analysts currently set an average price target of 13,77 USD for the Neogenomics stock (median: 14,28 USD), implying -16,1 % versus the latest price. The consensus is based on 17 analyst ratings.

Neogenomics Analist Fiyat Hedefleri 2026

17 analysts currently rate the Neogenomics stock: 8 recommend buying, 8 holding and 1 selling. For 2026, analysts expect Neogenomics to generate revenue of 800,44 M USD and earnings per share of 0,89 USD.

Neogenomics Analist Fiyat Hedefleri 2026

Converted at the current exchange rate, the Neogenomics share trades at 14,39 EUR (16,60 USD).

The Neogenomics share (NEO) is listed on 5 stock exchanges, including: NASDAQ (NEO), Frankfurt (NG9.F), München (NG9.MU), Düsseldorf (NG9.DU), SIX (Zürich) (NG9.SW).

Neogenomics Inc is a leading company in oncology diagnostics and offers a wide range of solutions and products to its customers. The company has been listed on the stock exchange since 2001 and is the largest provider of cancer diagnostics services in the United States. Translate the text to the best possible English.

beklenen'nin Neogenomics hasılatı 800,44 M USD'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.

beklenen'nin Neogenomics karı 22,80 M USD'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.

Neogenomics'nin Fiyat/Kazanç (F/K) oranı şu anda 18,73'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların Neogenomics hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.

Neogenomics'nin Fiyat/Satış (F/S) oranı şu anda 0,53'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve Neogenomics hisse senedinin değerleme metriği olarak hizmet eder.

Neogenomics'nin Eulerpool Kalite Puanı 3/10'dur.

Neogenomics'nin ISIN'i US64049M2098'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.

Neogenomics'nin WKN'i 120159'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.

Neogenomics'nin ticker'ı NEO'dir. Ticker sembolü, Neogenomics hisseleri borsada işlem görmek için kullanılır.

Neogenomics son 0 yıl boyunca her yıl temettü ödemiştir.

Neogenomics, 'Sağlık' sektörüne atanmıştır.

Neogenomics'un temettüleri USD cinsinden dağıtılır.